Reducing PSA-Based Prostate Cancer Screening in Men Aged 75 Years and Older with the Use of Highly Specific Computerized Clinical Decision Support

被引:23
|
作者
Shelton, Jeremy B. [1 ,2 ]
Ochotorena, Lee [1 ]
Bennett, Carol [1 ,2 ]
Shekelle, Paul [1 ]
Kwan, Lorna [2 ]
Skolarus, Ted [3 ]
Goldzweig, Caroline [1 ]
机构
[1] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA
[2] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA
[3] Vet Adm Ann Arbor Healthcare Syst, Hlth Serv Res & Dev, Ann Arbor, MI USA
关键词
electronic health records; physician decision support; cancer screening; applied informatics; implementation research; quality improvement; HEALTH INFORMATION-TECHNOLOGY; CARE; MORTALITY; ALERTS; INTERVENTIONS; PHYSICIANS; IMPLEMENT; BENEFITS; QUALITY; COSTS;
D O I
10.1007/s11606-015-3249-y
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
In 2012, the Veterans Health Administration (VHA) implemented guidelines seeking to reduce PSA-based screening for prostate cancer in men aged 75 years and older. To reduce the use of inappropriate PSA-based prostate cancer screening among men aged 75 and over. The Veterans Affairs Greater Los Angeles Healthcare System (VA GLA) We developed a highly specific computerized clinical decision support (CCDS) alert to remind providers, at the moment of PSA screening order entry, of the current guidelines and institutional policy. We implemented the tool in a prospective interrupted time series study design over 15 months, and compared the trends in monthly PSA screening rate at baseline to the CCDS on and off periods of the intervention. A total of 30,150 men were at risk, or eligible, for screening, and 2,001 men were screened. The mean monthly screening rate during the 15-month baseline period was 8.3 %, and during the 15-month intervention period, was 4.6 %. The screening rate declined by 38 % during the baseline period and by 40 % and 30 %, respectively, during the two periods when the CCDS tool was turned on. The screening rate ratios for the baseline and two periods when the CCDS tool was on were 0.97, 0.78, and 0.90, respectively, with a significant difference between baseline and the first CCDS-on period (p < 0.0001), and a trend toward a difference between baseline and the second CCDS-on period (p = 0.056). Implementation of a highly specific CCDS tool alone significantly reduced inappropriate PSA screening in men aged 75 years and older in a reproducible fashion. With this simple intervention, evidence-based guidelines were brought to bear at the point of care, precisely for the patients and providers for whom they were most helpful, resulting in more appropriate use of medical resources.
引用
收藏
页码:1133 / 1139
页数:7
相关论文
共 50 条
  • [21] ERSPC-Studie – PSA(prostataspezifisches Antigen)-basiertes Prostatakarzinom-Screening bei älteren PatientenERSPC trial—prostate-specific antigen (PSA)-based prostate cancer screening in older men
    Jan Philipp Radtke
    Analena Elisa Handke
    Friederike Haidl
    Peter Albers
    Die Urologie, 2024, 63 (11) : 1155 - 1157
  • [22] Prostate Cancer Mortality in Men Aged 70 Years Who Recently Underwent Prostate-Specific Antigen Screening
    Chung, Dana H.
    Caverly, Tanner J.
    Schipper, Matthew J.
    Hofer, Timothy P.
    Gulati, Roman
    Rose, Brent S.
    Caram, Megan E. V.
    Tsao, Phoebe A.
    Stensland, Kristian D.
    Elliott, David
    Saini, Sameer D.
    Bryant, Alex K.
    JAMA NETWORK OPEN, 2025, 8 (02)
  • [23] Can Comprehensive Geriatric Assessment Predict Tolerance of Radiotherapy for Localized Prostate Cancer in Men Aged 75 Years or Older?
    Goineau, Aurore
    Campion, Loic
    Commer, Jean-Marie
    Vie, Brigitte
    Ghesquiere, Agnes
    Bera, Guillaume
    Jaffres, Didier
    Magne, Nicolas
    Artignan, Xavier
    Chamois, Jerome
    Bergerot, Philippe
    Crehange, Gilles
    Deniaud-Alexandre, Elisabeth
    Buthaud, Xavier
    Belkacemi, Yazid
    Dore, Melanie
    De Decker, Laure
    Supiot, Stephane
    CANCERS, 2020, 12 (03)
  • [24] "PSA Surveillance in the Septuagenarian": A Proposed New Terminology for Clinical Follow-up to Assess Risk of Prostate Cancer in Men Aged 70 Years and Older
    Carlsson, Sigrid V.
    Eastham, James A.
    Crawford, E. David
    Harris, Richard G.
    EUROPEAN UROLOGY, 2020, 78 (02) : 136 - 137
  • [25] Evaluation of prostate-specific antigen density in the diagnosis of prostate cancer combined with magnetic resonance imaging before biopsy in men aged 70 years and older with elevated PSA
    Yanai, Yoshinori
    Kosaka, Takeo
    Hong, Hiroshi
    Matsumoto, Kazuhiro
    Shinojima, Toshiaki
    Kikuchi, Eiji
    Miyajima, Akira
    Mizun, Ryuichi
    Mikami, Shuji
    Jinzaki, Masahiro
    Oya, Mototsugu
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 9 (06) : 656 - 660
  • [26] PROSTATE-SPECIFIC ANTIGEN (PSA) LEVELS IN MEN AGED 60 TO 70 AND DEVELOPMENT OF LETHAL PROSTATE CANCER OVER 30 YEARS: IMPLICATIONS FOR RISK-STRATIFIED SCREENING
    Preston, Mark
    Downer, Mary Kathryn
    Gerke, Travis
    Carlsson, Sigrid
    Sesso, Howard
    Kibel, Adam
    Trinh, Quoc-Dien
    Lilja, Hans
    Vickers, Andrew
    Wilson, Kathryn
    Mucci, Lorelei
    JOURNAL OF UROLOGY, 2017, 197 (04): : E487 - E488
  • [27] Men's Use of an Internet-Based Decision Aid for Prostate Cancer Screening
    Kassan, Elisabeth C.
    Williams, Randi M.
    Kelly, Scott P.
    Barry, Samantha A.
    Penek, Sofiya
    Fishman, Mary B.
    Cole, Carmella A.
    Miller, Edward M.
    Taylor, Kathryn L.
    JOURNAL OF HEALTH COMMUNICATION, 2012, 17 (06) : 677 - 697
  • [28] Use of the Prostate-Specific Antigen Test Among Men Aged 75 Years or Older in the United States: 2006 Behavioral Risk Factor Surveillance System
    Li, Jun
    Zhao, Guixiang
    Pollack, Lori A.
    Smith, Judith Lee
    Joseph, Djenaba A.
    PREVENTING CHRONIC DISEASE, 2010, 7 (04):
  • [29] Can prostate-specific antigen and prostate-specific antigen velocity be used for prostate cancer screening in men older than 70 years?
    Mouraviev, Vladimir
    Broadwater, Gloria
    Sun, Leon
    Mayes, Janice M.
    Moul, Judd W.
    Polascik, Thomas J.
    UROLOGY, 2008, 71 (06) : 1020 - 1023
  • [30] Development and validation of a clinical decision support system based on PSA, microRNAs, and MRI for the detection of prostate cancer
    Mazzetti, Simone
    Defeudis, Arianna
    Nicoletti, Giulia
    Chiorino, Giovanna
    De Luca, Stefano
    Faletti, Riccardo
    Gatti, Marco
    Gontero, Paolo
    Manfredi, Matteo
    Mello-Grand, Maurizia
    Peraldo-Neia, Caterina
    Zitella, Andrea
    Porpiglia, Francesco
    Regge, Daniele
    Giannini, Valentina
    EUROPEAN RADIOLOGY, 2024, 34 (8) : 5108 - 5117